Cytomx Thera (CTMX) Stock Price, Quote & News

Company Profile

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index f...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 515 3185

Fax: 650 351 0353

Website: www.cytomx.com

Address:

151 Oyster Point Boulevard, Suite 400, South San Francisco, United States

Turdsniffer Nov. 13 at 6:33 PM

$CTMX no lube today 😐

0 · Reply

obryanjfg Nov. 13 at 6:04 PM

$CTMX Would anyone be able to comment on the next event or readout? Starting a pos, but going slow.

0 · Reply

winners18 Nov. 13 at 1:13 PM

$CTMX sold mrsn at $27. My third ADC cos got acquired. Imgn,Immu,Mrsn. Three more to go: ctmx,mgnx,bcab

1 · Reply

DanilaMaster Nov. 13 at 1:05 PM

$CTMX will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025 , at 9:00 a.m. GMT .

0 · Reply

crockpot7 Nov. 12 at 9:04 PM

$CTMX 33100 shares @ 4.23 at 16:01:49...

0 · Reply

winners18 Nov. 12 at 4:23 PM

$CTMX

0 · Reply

MichaelSctock Nov. 12 at 1:26 AM

$CTMX 🍻

1 · Reply

bryantboy99 Nov. 12 at 12:19 AM

$CTMX shorts are going to be in trouble https://x.com/semodough/status/1988378464110674328?t=5vWbxgk7BcwpoPwyQooDHQ&s=19

0 · Reply

Dubbyy Nov. 11 at 6:23 PM

$RVPH same flow of $CTMX

0 · Reply

atco1982 Nov. 11 at 3:39 PM

$CTMX The Target price for this will be 50, when the 100 patient Stage 1 trial is 70% sucessful with 10% side effects. Actually 50 +++. Until then, all numbers are fake.@bryantboy99

1 · Reply

CytomX Therapeutics to Present at the Jefferies London Healthcare Conference

Nov 11, 2025, 4:04 AM EST - 3 days ago

Targeting Adhesion Molecules With ADC's: The Bet Of CytomX

Nov 7, 2025, 2:26 PM EST - 6 days ago

CytomX Therapeutics, Inc. (CTMX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:10 PM EST - 7 days ago

CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 3:15 PM EST - 9 days ago

Top Biotech Stocks Riding The Rally

GRAL GRFS INCY

Nov 4, 2025, 9:15 AM EST - 10 days ago

CytomX Therapeutics to Present CX-801 Phase 1 Monotherapy Biomarker Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 30, 2025, 8:00 AM EDT - 15 days ago

CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 20, 2025, 4:05 PM EDT - 24 days ago

CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer

Oct 13, 2025, 11:45 PM EDT - 4 weeks ago

CytomX Therapeutics: Additional Run Up Into The Q1 2026 Readout Is Possible

Oct 12, 2025, 5:00 AM EDT - 4 weeks ago

Renewed Tariff Fears Spotlight Top Performing Stocks Since April

COMM NVDA PSIX SMH VSAT

Oct 6, 2025, 11:20 AM EDT - 5 weeks ago

CytomX: A Fresh Start With New Drugs After Total Pipeline Failure

Sep 10, 2025, 4:26 PM EDT - 2 months ago

CytomX Therapeutics, Inc. (CTMX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 28, 2025, 8:00 AM EDT - 2 months ago

CytomX Therapeutics to Present at Upcoming September Investor Conferences

Aug 13, 2025, 8:00 AM EDT - 3 months ago

CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study

Aug 8, 2025, 6:10 PM EDT - 3 months ago

CytomX Therapeutics, Inc. (CTMX) Q2 2025 Earnings Call Transcript

Aug 8, 2025, 5:05 PM EDT - 3 months ago

CytomX Therapeutics: Updated Outlook For Late 2025

Aug 7, 2025, 4:10 PM EDT - 3 months ago

CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

Jul 31, 2025, 8:00 AM EDT - 3 months ago

CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025

May 29, 2025, 8:00 AM EDT - 6 months ago

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

May 19, 2025, 8:00 AM EDT - 6 months ago

CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma

May 13, 2025, 10:34 AM EDT - 6 months ago

CytomX Therapeutics: Doubling Overnight On Phase 1 Data

May 12, 2025, 2:40 PM EDT - 6 months ago

CytomX Therapeutics, Inc. (CTMX) CX-2051 Phase 1 Interim Clinical Data Call (Transcript)

May 12, 2025, 11:11 AM EDT - 6 months ago

Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report

May 12, 2025, 6:50 AM EDT - 6 months ago

CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock

May 12, 2025, 6:15 AM EDT - 6 months ago

CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)

May 12, 2025, 6:15 AM EDT - 6 months ago

CytomX Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 8:00 AM EDT - 6 months ago

CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025

Apr 28, 2025, 4:00 PM EDT - 7 months ago

CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting

Mar 6, 2025, 6:34 PM EST - 9 months ago

CytomX Therapeutics, Inc. (CTMX) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:10 PM EST - 9 months ago

CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update

Mar 5, 2025, 8:00 AM EST - 9 months ago

CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference

Feb 27, 2025, 8:00 AM EST - 9 months ago

CytomX Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025

Jan 6, 2025, 4:05 PM EST - 11 months ago

CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate Update

Nov 27, 2024, 8:00 AM EST - 1 year ago

CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference

Nov 8, 2024, 8:44 AM EST - 1 year ago

CytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:10 PM EST - 1 year ago

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Sep 9, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid Tumors

Aug 8, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 18, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

Jun 17, 2024, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

May 16, 2024, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Announces New Employment Inducement Grants

May 9, 2024, 9:10 AM EDT - 1 year ago

CytomX stock down 30% despite encouraging cancer study results

May 8, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 8, 2024, 4:10 PM EDT - 1 year ago

CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)

May 7, 2024, 4:15 PM EDT - 1 year ago

CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)

May 1, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024

Apr 25, 2024, 6:33 PM EDT - 1 year ago

CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town

Apr 8, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces First Patient Dosed with CX-2051, a Conditionally Activated EpCAM-Directed ADC, in a Phase 1 Study in Patients with Advanced Solid Tumors

Apr 3, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas

Mar 21, 2024, 8:00 AM EDT - 1 year ago

CytomX Therapeutics Appoints Dr. Zhen Su to Board of Directors

Turdsniffer Nov. 13 at 6:33 PM

$CTMX no lube today 😐

0 · Reply

obryanjfg Nov. 13 at 6:04 PM

$CTMX Would anyone be able to comment on the next event or readout? Starting a pos, but going slow.

0 · Reply

winners18 Nov. 13 at 1:13 PM

$CTMX sold mrsn at $27. My third ADC cos got acquired. Imgn,Immu,Mrsn. Three more to go: ctmx,mgnx,bcab

1 · Reply

DanilaMaster Nov. 13 at 1:05 PM

$CTMX will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Thursday, November 20, 2025 , at 9:00 a.m. GMT .

0 · Reply

crockpot7 Nov. 12 at 9:04 PM

$CTMX 33100 shares @ 4.23 at 16:01:49...

0 · Reply

winners18 Nov. 12 at 4:23 PM

$CTMX

0 · Reply

MichaelSctock Nov. 12 at 1:26 AM

$CTMX 🍻

1 · Reply

bryantboy99 Nov. 12 at 12:19 AM

$CTMX shorts are going to be in trouble https://x.com/semodough/status/1988378464110674328?t=5vWbxgk7BcwpoPwyQooDHQ&s=19

0 · Reply

Dubbyy Nov. 11 at 6:23 PM

$RVPH same flow of $CTMX

0 · Reply

atco1982 Nov. 11 at 3:39 PM

$CTMX The Target price for this will be 50, when the 100 patient Stage 1 trial is 70% sucessful with 10% side effects. Actually 50 +++. Until then, all numbers are fake.@bryantboy99

1 · Reply

bryantboy99 Nov. 11 at 1:17 PM

$CTMX do yourself a favor and take a look at the latest presentation that is on the website and tell me how you can not be bullish on this company. I know it has ran up a bunch but the future looks solid. https://ir.cytomx.com/events-and-presentations

2 · Reply

lidopete Nov. 11 at 1:00 PM

$CTMX 06:18 Recommendations CytomX Therapeutics price target raised to $10 from $5 at H.C. Wainwright, enrollment expansion: H.C. Wainwright analyst Mitchell Kapoor raised the firm's price target on CytomX Therapeutics to $10 from $5 and keeps a Buy rating on the shares. The firm says "strong" CX-2051 trial demand and expansion of enrollment to 100 patients should provide a stronger signal for an approval path.

1 · Reply

JarvisFlow Nov. 11 at 12:41 PM

HC Wainwright & Co. updates rating for CytomX Therapeutics ( $CTMX ) to Buy, target set at 5 → 10.

2 · Reply

buymoremakemore Nov. 10 at 9:47 PM

$CTMX Nice recovery since ER.

0 · Reply

bryantboy99 Nov. 10 at 9:10 PM

$CTMX

0 · Reply

Turdsniffer Nov. 10 at 8:53 PM

$CTMX oh hell yes daddy

0 · Reply

FonsieTrader Nov. 10 at 4:20 PM

🔥 $CTMX setting up beautifully here! Textbook ascending triangle breakout on the weekly — price reclaiming trendline support with strong OBV + MFI confirmation and ADX momentum heating up again. 💥 Above $4 = trigger zone for continuation toward $5.50–$6 short term. Bulls clearly in control — volume doesn’t lie. #CTMX #BreakoutSetup #FonsieTrends #Momentum

0 · Reply

Turdsniffer Nov. 10 at 2:31 PM

$CTMX

1 · Reply

lidopete Nov. 10 at 12:57 PM

$CTMX THE FLY 📷CytomX Therapeutics price target raised to $6.50 from $5 at Piper Sandler. Piper Sandler raised its price target on CytomX Therapeutics to $6.50 from $5 and maintained an Overweight rating on the shares. At SITC, CytomX presented Phase I data on Probody masked IFNalpha2b CX-801 in melanoma and preclinical data on Probody CDH3 T-cell engager CX-908. CytomX will present Phase I CX-801 data in combination with KEYTRUDA in advanced melanoma patients next year. Initial Phase I data on Probody masked EpCAM ADC CX-2051 showed doses of 7.2-10mg/kg achieved an impressive 28% ORR, 94% DCR and preliminary mPFS of 5.8 months in 3rd-line+ metastatic colorectal cancer. Related artic 7:52 AM · Nov 10, 2025

0 · Reply

Quantumup Nov. 10 at 12:50 PM

Piper Sandler⬆️the PT on $CTMX to $6.5 from $5, reiterated at an Overweight rating, and said, 'Encouraging CX-801 Data @ SITC, More CX-2051 Data in 1Q:26' $MRK $RHHBY Piper Sandler added:

1 · Reply

SofaKing_Nuts Nov. 10 at 12:02 PM

$CTMX did anyone catch the CX-801 presentation from this weekend?

1 · Reply

shortkiller7 Nov. 10 at 11:55 AM

$CTMX add 100k

2 · Reply

Market Cap	716.71M
Revenue (ttm)	138.10M
Net Income (ttm)	31.87M
EPS (ttm)	N/A
PE Ratio	10.25
Forward PE	136.67
Profit Margin	23.08%
Debt to Equity Ratio	0.00

Volume	3,868,800
Avg Vol	3,955,192
Day's Range	N/A - N/A
Shares Out	169.44M
Stochastic %K	40%
Beta	2.29
Analysts	Strong Sell
Price Target	$7.07